Navigation Links
Collexis Connects the NIH Clinical and Translational Science Award Programs with CTSA Expert Platform
Date:3/3/2009

COLUMBIA, S.C., March 3 /PRNewswire-FirstCall/ -- Collexis Holdings Inc. (OTC Bulletin Board: CLXS), a leading developer of semantic search and knowledge discovery software, announced today the launch of the world's first CTSA Experts Platform drawing on the research profiles of 38 institutions and their more than 60,000 life science researchers. The platform is available to Collexis clients who are also winners of the Clinical Translational Science Awards (CTSA's) from the National Institutes of Health. Institutions that are subscribers to the service will be able to search, rank, and visualize expert profiles from all 38 CTSA institutions.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090107/CLW051LOGO )

"Among the goals of the National Institutes of Health CTSA awards are to accelerate bench to bedside discoveries into patient care, as well as to develop the infrastructure to support ongoing collaborative efforts in biomedical research," said Dr. Christian Herzog, Managing Director at Collexis. "The Collexis CTSA Expert Platform will allow participants to achieve these important goals by matching basic researchers and clinical scientists within organizations, and across multiple awarded institutions."

The new offering gives CTSA users a unique competitive advantage. It allows a researcher to identify partners from their organization and across the CTSA Consortia on any biomedical research topic(s). The platform automatically recommends collaborators from other institutions based on multiple areas of common research interests. Finally, the system will track and identify collaboration patterns among CTSA consortia members, allowing Collexis to give clients and NIH more information about how researchers work together and signaling ways that NIH can improve the CTSA program.

The Collexis Expert Platform approach to profiling life science researchers has become the standard with research intensive institutions. Current clients include Johns Hopkins, the National Institutes of Health, University of Michigan, Oregon Health Sciences University, The Medical College of Georgia, The University of Miami, the University of South Carolina, and over 25 more leading medical research institutions.

About Collexis Holdings, Inc.

Collexis Holdings, Inc., a leading developer of semantic search and knowledge discovery software is headquartered in Columbia, South Carolina (USA) with operations in Cincinnati, Ohio and Cologne, Germany. Collexis now offers the world's first pre-populated scientific social network for life science researchers, www.biomedexperts.com. Collexis' proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis' current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, visit www.collexis.com.

Disclaimer: National Institutes of Health (NIH) is not considered a supporter or partner of Collexis. Reference to NIH in the above shall not be construed as a Government endorsement nor does it obligate NIH to a position on or about the Collexis Software.

Forward-Looking Statements

Some of the statements made in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and include known and unknown risks, uncertainties and other factors, many of which the company is unable to predict or control, that may cause the company's actual results or performance to differ materially from any future results or performance expressed or implied by such forward-looking statements. These statements involve risks and uncertainties, including risks and uncertainties associated with the company's CTSA Experts Platform. These risks and uncertainties are in addition to other factors detailed from time to time in the company's filings with the SEC, including the section entitled "Risk Factors" in its transition report on Form 10-K for the period ended June 30, 2008. The company cautions investors that any forward-looking statements made by the company are not necessarily indicative of future performance. The company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.


'/>"/>
SOURCE Collexis Holdings Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. American Association for Cancer Research (AACR) Deploys Collexis Reviewer Finder and Journal Dashboard Applications
2. BioFlorida Selects Collexis BiomedExperts.com as the Primary Professional Network for its 200 Member Companies and Organizations
3. Carbon nanotubes outperform copper nanowires as interconnects
4. Clinical Research Staffing Firm ASG Acquires CRO Ockham Development Group
5. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
6. Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain
7. Implicit Licenses Clinical Stage Antibody Program From Lilly
8. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
9. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
10. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
11. M2S Expert gives address "Applying the Principles of Six Sigma in the Imaging Core Lab" at Imaging for Clinical Trials conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... ... Drug Safety Technology Consortium™ (SafeTEC™), $3 million in investment towards 15+ TEC Validation ... tools and assays, and their applicability in drug safety assessment, for the industry ...
(Date:1/16/2017)... NY (PRWEB) , ... January 16, 2017 , ... ... New Jersey laws precedential publication its decision on the appeal filed by India-based ... lawsuit of breach of contract against DPCL and one of its Dishman Group’s ...
(Date:1/14/2017)... , Jan. 13, 2017  The Alliance for ... in response to FDA final guidance on ... its continued leadership in emphasizing the importance of distinct ... keenly aware of the benefits biosimilars will bring to ... Yet the portion of the Guidance dealing ...
(Date:1/13/2017)... Island, NY (PRWEB) , ... January 13, 2017 ... ... teamed up with several companies to offer its customers three new solutions for ... probe would come in handy if a customer has an oddly-shaped sample that ...
Breaking Biology Technology:
(Date:1/4/2017)... -- For the thousands of attendees at this year,s International Consumer Electronics Show ... biometric measurement devices and services, will be featuring its new line of ... Medical,s special CES Exhibit Suite , the new upper arm and ... WellnessConnected product platform.  Continue ... ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its longstanding ... leading personal genetics company, recently released its latest children,s book, ... The book focuses on the topics of inheritance and variation ... Standards (NGSS) taught in elementary school classrooms in the US. ... series by illustrator Ariana Killoran , whose previous book ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
Breaking Biology News(10 mins):